Drug intelligence / Profile preview

Novel Peptide COVID-19 Therapeutic

Development stage: Preclinical
Lead developer: Hoth Therapeutics
Modality: Peptides
Administration: Intranasal, Inhalation, Oral, Buccal, Vaginal, Transdermal, Ophthalmic

Overview

Novel Peptide COVID-19 Therapeutic is a peptide-based therapeutic being developed to prevent the binding of the SARS-CoV-2 spike protein, a primary mechanism by which the virus infects cells and causes COVID-19. Hoth Therapeutics licensed exclusive worldwide rights to this novel peptide technology from Virginia Commonwealth University (VCU) and is collaborating with VCU on its preclinical research and development. The research is led by Dr. Michael Peters at VCU Massey Cancer Center, aiming to create an effective therapeutic against the COVID-19 pandemic.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on Novel Peptide COVID-19 Therapeutic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel Peptide COVID-19 Therapeutic.

Explore the full profile